Nutrition 29 (2013) 1133-1141



Contents lists available at ScienceDirect

Nutrition



journal homepage: www.nutritionjrnl.com

Applied nutritional investigation

The association of sleep duration and cardiometabolic risk factors in a national sample of children and adolescents: The CASPIAN III Study

Leila Azadbakht Ph.D.^a, Roya Kelishadi M.D.^{b.*}, Mahdieh Khodarahmi M.Sc.^a, Mostafa Qorbani Ph.D.^c, Ramin Heshmat Ph.D.^d, Mohammad Esmaeil Motlagh M.D.^e, Mahnaz Taslimi M.Sc.^b, Gelayol Ardalan M.D., M.P.H^b

^a Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran ^b Pediatrics Department, Faculty of Medicine and Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

^c Department of Public Health, Alborz University of Medical Sciences, Karaj, Iran

^d Epidemiology Department, Chronic Diseases Research Center, Endocrinology & Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran ^e Pediatrics Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

ARTICLE INFO

Article history: Received 20 November 2012 Accepted 5 March 2013

Keywords: Sleep duration Cardiovascular risk factors Adolescent Children

ABSTRACT

Objectives: Although sleep duration is one of the most important health-related factors, its association with risk factors for chronic diseases has not been completely clarified, especially among children and adolescents. The aim of this study was to evaluate the association between sleep duration and CVD risk factors among a nationally representative sample of Iranian children and adolescents.

Methods: This cross-sectional national study was performed on a representative sample of 5528 Iranian students, ages 10 to 18 y living in central cities of 27 provinces of Iran. Physical examinations and laboratory tests were performed using standard protocols. To determine the association between sleep duration and cardiometabolic risk factors, multivariable logistic regression was used and odds ratios (OR; with 95% confidence intervals) are reported.

Results: The mean \pm SD age was not significantly different among boys (14.69 \pm 2.45 y) and girls (14.7 \pm 2.38 y). In a crude model, boys who slept > 8 h and 5 to 8 h had lower OR for abdominal obesity compared with those who had slept <5 h in a crude model (ORs, 0.70, 0.80, 1.0, respectively; P = 0.008). A similar result was observed in an age- adjusted model for the prevalence of abdominal obesity (ORs, 0.69, 0.76, 1.0, respectively; P = 0.011). Girls who had slept > 8 h per day had lower OR for high serum low-density lipoprotein levels compared with those who slept < 5 h per day (P = 0.002). These differences remained significant even in the fully adjusted model for all the confounding variables (P = 0.008). Moreover, among boys ages 10 to 14 y, longer sleep duration increased the risk for high total cholesterol in all models.

Conclusion: Shorter sleep duration increased the risk for some cardiometabolic risk factors among adolescents. The clinical significance of our findings should be determined in longitudinal studies. © 2013 Elsevier Inc. All rights reserved.

Introduction

Currently, cardiovascular diseases (CVDs) are identified as the most common cause of death, worldwide. CVDs are the most common cause of morbidity, mortality, and disability with high health care costs both in developed and developing countries [1]. The trend for overweight and obesity, which predicts CVDs among Iranian children and adolescents, doubled from 1993 to

0899-9007/\$ - see front matter \odot 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.nut.2013.03.006 1999. Studies have indicated that about 80% of obese children are suffering from at least one confirmed CV risk factor [2]. Prospective and retrospective studies have shown that roots of CV risk factors including diabetes, dyslipidemia, hypertension, and overweight can be influenced by lifestyle-related factors in childhood [1,3,4].

Dietary habits, physical activity status, smoking, and sleep duration are considered CV risk factors [5]. Little sleep, lack of sleep, and changes in sleep duration are common problems seen in both adults and children in different countries [6,7]. The effective factors on this alteration contain changing lifestyle

^{*} Corresponding author. Tel.: +983117923060; fax: +983116687898. *E-mail address:* kelishadi@med.mui.ac.ir (R. Kelishadi).

because of rapid urbanization, modernization, technological transformation, and limited outdoor activities [8]. Increases in households with two wage earners and elevated prevalence of shift work are responsible factors for a greater reduction in mean sleep time among adults [6]. Time spent watching television, listening to radio, and on the Internet are effective factors on these changes in children [6]. Children and adolescents are especially vulnerable because their habits and lifestyles form during this critical period [9]. Epidemiologic studies on children and adolescents have reported a consistent and strong relationship of sleep deprivation to both concurrent and future obesity [10]. Other studies have indicated that obese children have dyslipidemia, higher blood pressure, higher fasting glucose and insulin, and higher atherosclerotic risk factors [11]. Studies have shown that children ages 3.6 to 18.5 y with less sleep duration have more insulin resistance than children with normal sleep times [12]. A cross-sectional study found an inverse association between sleep duration and waist circumference (WC) in Chinese school children and adolescents ages 6 to 20 y [9]. Reverse relationships of sleep duration and hypertension, which was reported among adults, also was shown among boys ages 11 to 14 y [13]. Evidence has indicated that less sleep duration enhances the risk for hypercholesterolemia. Wish et al recently showed that shorter sleep duration resulted in increase hypercholesterolemia in a longitudinal study of adolescents [9]. To our knowledge, there is limited information about effects of sleep duration on lipid profiles of children and adolescents.

Studies in adults have indicated a relationship between sleep duration and metabolic syndrome and diabetes. However, few studies found this association in children and adolescents [14, 15]. The population of Iran is extremely young. More than 32% of the population is under age 15 y and 12% are school aged [8]. Conducting studies among the young population therefore is important in this country. According to our knowledge, there is no published data from Iran that provides information about the relationship between sleep duration and CV risk factors, especially in children. Therefore, this study was conducted to examine the association between sleep duration and CV risk factors in Iranian school-aged (10–18 y) children.

Methods

This study was conducted using the data from a longitudinal national project, CASPIAN III (Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable disease). This nationwide health survey was a school-based program that was conducted in 27 Iranian provinces. The comprehensive methodology of this study has been published previously [16], and here we just briefly describe it. The present study included 5528 students ages 10 to 18 y. They were recruited by multistage random cluster sampling from urban and rural areas of 27 provincial counties in Iran. We randomly selected eligible schools for our study from a list of schools that were stratified according to the information bank of the Ministry of Education. Students also were selected randomly from each school. Those students who had any chronic disease or who were taking medications were not included in this study. This project was approved by the ethnic committees and orler relevant national regulatory organizations. Written inform consent and oral assent was obtained from parents and students, respectively.

Assessment of anthropometric measurements

We measured the weighta of students while they were wearing light clothes twice. Measurements were done without wearing shoes by digital scale and averaged to the nearest 0.2 kg. Height was measured in duplicate without shoes while the students were standing and the shoulders were in normal position. Body mass index (BMI) was calculated as weight (in kg) divided by squared of height (in m²). WC was measured at a level midway between the lower rib margin and iliac crest to the nearest 0.5 cm. The maximum level of hip without any pressure to the body surface to the nearest 0.5 cm was considered for measuring hip circumference.

Assessment of biomarkers

Students were requested to attend the nearest health center to their school. All students were instructed to fast for 12 h before blood sampling. The antecubital vein was considered for blood sampling. This was done between 08:00 and 09:30. All blood samples were centrifuged for 10 min at 3000 g within 30 min of venipuncture. We measured lipid profile levels including high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) by auto-analyzers. HDL-C was measured after precipitation of non-HDL-C with dextran sulphatemagnesium chloride. Low-density lipoprotein cholesterol (LDL-C) in serum samples with TG \leq 400 mg/dL was calculated according to Friedwald equation. Fasting blood sugar (FBS) and total cholesterol (TC) were measured by autoanalyzer. Central Provincial Laboratory, which follows the standards of the National Reference Laboratory, a World Health Organization (WHO)-Collaborating center in Tehran, was used for analyzing. The Data and Safety Monitoring Board of the project has taken into account for different levels of quality control. A comprehensive operation manual was provided for the study team. Based on standard guidelines, a group of external evaluation and supervisor nominated by two collaborating ministries checked the performance of the personnel, and monitored and calibrated equipment.

Assessment of blood pressure

For measuring systolic and diastolic blood pressure (SBP; DBP) we requested patients to be seated and calm, with appropriate cuff sizes according to arm size. BPs were measured twice after more than 5 min rest. A trained technician measured SBP by defining the clear of the first sound (first Korotkoff phase) and DBP by defining as disappearance of sound (fifth Korotkoff phase). We recorded the average of two measurements.

Assessment of sociodemographic variables and sleep duration

The questionnaire was prepared based on the WHO STEPwise approach to NCD (Tools ver 9.5) and WHO Global School Health Survey (GSHS). The questions concerning the sociodemographic characteristics and sleep duration were included in the "parents' questionnaire," which was added to the previously mentioned questionnaires [17]. The validity and reliability of all questionnaires have been confirmed in the first survey of this surveillance system. Trained health care providers questioned parents about variables related to sociodemographic issues and past history (e.g. maternal education, child's birth weight, family dietary habits, family history of obesity and other chronic disease, as well as sleep duration). Sleep duration was categorized in three groups from <5 h, 5 to 8 h, and >8 h.

Definition of risk factors

The Centers for Disease Control and Prevention (CDC) provided the BMI percentiles for the classification of the children and adolescents as underweight, normal, overweight, and obese [18]. To evaluate the pattern of physical activity, three indicators were used including:

- 1. hours of physical education at school;
- 2. hours of watching television at home; and
- 3. hours spent on sports club training.

By using principle component analysis, we obtained a score for physical activity. The mean of this score is presented in Table 1.

Abnormal serum lipids were defined as a TC, LDL-C and or TG higher than the level corresponding to the age and gender-specific 95th percentile, also HDL-C lower than age and gender-specific 5th percentile [19]. High fasting blood sugar (FBS) was determined with levels \geq 100 mg/dL [20]. The average SBP or DBP above the 90th percentile for that age and gender after adjusting for weight and height was considered elevated BP [21].

Statistical analysis

General characteristics of boys and girls were analyzed separately by sleep duration categories including <5 h, 5 to 8 h and >8 h. We performed one-way analysis of variance (ANOVA) with post hoc tests to evaluate significant differences in general features (e.g., age, BMI, WC, weight, and height) according to sleep duration categories. We reported $\chi 2$ test for significant differences of qualitative characteristics as a percentage according to sleep duration. ANOVA was used to report the mean serum lipid profile and glucose levels as well as BP with 95% confidence interval (CI) according to different sleep duration groups. To determine the association between several risk factors of CVD and sleep duration, multivariable logistic regression and odds ratios (OR; with 95% CI) was used. *P* for trend was reported to investigate dose–response correlation between CVD risk

Demographic characteristics and physical activity of participants according to sleep duration categories,* all of the ages 10-18 y: The CASPIAN-III Study

	Sleep duration (h/d)			P-value [†]
	<5	5-8	>8	
Boys				
Age (y)	14.4 ± 2.2	14.9 ± 2.4	14.6 ± 2.5	0.450
Weight (kg)	45.8 ± 12.7	46.7 ± 13.6	45.5 ± 13.1	0.137
WC (cm)	69.6 ± 14.3	67.7 ± 11.9	$\textbf{67.4} \pm \textbf{26.3}$	0.314
BMI (kg/m ²)	19.2 ± 4.2	19.9 ± 4.3	19.5 ± 4.0	0.015
Physical activity (%)	0.5 ± 0.8	$\textbf{0.6} \pm \textbf{1.1}$	-0.3 ± 0.8	0.000
Family history				
Diabetes (%)	5.5	26.9	67.6	0.010
Obesity (%)	4.3	27.7	68	0.475
Hyperlipidemia (%)	5.2	28.7	66.1	0.002
Hypertension (%)	6.0	27.7	66.2	0.000
Osteoporosis (%)	5.4	30.1	64.5	0.004
Girls				
Age (y)	14.4 ± 2.1	14.9 ± 2.3	14.6 ± 2.4	0.269
Weight (kg)	46.2 ± 15.2	49.4 ± 16.2	$\textbf{47.6} \pm \textbf{16.9}$	0.351
WC (cm)	69.0 ± 10.6	70.1 ± 11.5	69.7 ± 22.6	0.981
BMI (kg/m ²)	18.9 ± 3.7	19.5 ± 4.0	19.1 ± 4.1	0.263
Physical activity (%)	$\textbf{0.4}\pm\textbf{0.9}$	0.6 ± 1.2	-0.3 ± 0.7	0.000
Family history				
Diabetes (%)	6.2	27.2	66.6	0.001
Obesity (%)	5.7	25.1	69.2	0.119
Hyperlipidemia (%)	7.3	25.4	67.3	0.001
Hypertension (%)	5.7	26.7	67.6	0.020
Osteoporosis (%)	7.2	31.3	61.6	0.000

ANOVA, analysis of variance; BMI, body mass index; WC, waist circumference Sleep duration.

P-value are resulted from ANOVA.

factors and sleep duration. In multivariable logistic regression, we used a crude model without adjustment and three additionally adjusted models for several potential confounders. Statistical analysis was performed using the SPSS for Windows software (version 16.0. SPSS, Chicago, IL), and P < 0.05 was considered statistically significant.

Table 2

Demographic characteristics and physical activity of participants according to sleep duration categories,* ages 10-14 y: The CASPIAN-III Study

	Sleep duration (h/d)			P-value [†]
	<5	5-8	>8	
Boys				
Age (y)	12.6 ± 1.1	12.4 ± 1.2	12.3 ± 1.2	0.070
Weight (kg)	$\textbf{39.4} \pm \textbf{12.2}$	$\textbf{37.9} \pm \textbf{11.1}$	$\textbf{37.6} \pm \textbf{11.4}$	0.257
WC (cm)	$\textbf{67.0} \pm \textbf{17.2}$	$\textbf{63.4} \pm \textbf{11.4}$	$\textbf{62.8} \pm \textbf{17.3}$	0.056
BMI (kg/m ²)	18.6 ± 4.3	18.0 ± 3.7	17.9 ± 3.9	0.214
Physical activity (%)	$\textbf{0.6} \pm \textbf{0.9}$	0.6 ± 1.1	-0.3 ± 0.8	0.000
Family history				
Diabetes (%)	7.6	24.3	68.1	0.048
Obesity (%)	4.9	25.2	69.9	0.519
Hyperlipidemia (%)	7.6	25.1	67.3	0.002
Hypertension (%)	8.3	23.3	68.4	0.000
Osteoporosis (%)	7.9	26.6	65.5	0.037
Girls				
Age (y)	12.7 ± 0.9	12.6 ± 1.1	12.5 ± 1.2	0.015
Weight (kg)	$\textbf{36.8} \pm \textbf{9.5}$	$\textbf{38.3} \pm \textbf{11.5}$	$\textbf{36.5} \pm \textbf{10.4}$	0.074
WC (cm)	64.3 ± 9.2	65.8 ± 11.3	64.5 ± 22.9	0.580
BMI (kg/m ²)	17.5 ± 2.9	18.3 ± 3.8	17.5 ± 3.6	0.083
Physical activity (%)	$\textbf{0.4} \pm \textbf{0.9}$	0.6 ± 1.3	-0.4 ± 0.7	0.000
Family history				
Diabetes (%)	6.2	25.2	68.6	0.136
Obesity (%)	6.0	21.9	72.1	0.537
Hyperlipidemia (%)	7.7	21.9	70.3	0.020
Hypertension (%)	6.2	23.6	70.3	0.369
Osteoporosis (%)	6.1	27.3	66.7	0.051

ANOVA, analysis of variance; BMI, body mass index; WC, waist circumference Sleep duration.

[†] P-value are resulted from ANOVA.

Table 3

Demographic characteristics and physical activity of participants according to sleep duration categories,* ages 14-18 years: The CASPIAN-III Study

	Sleep duration (h/d)			P-value [†]
	<5	5–8	>8	
Boys				
Age (y)	16.3 ± 1.2	16.7 ± 1.2	16.7 ± 1.2	0.210
Weight (kg)	52.2 ± 9.7	53.3 ± 11.4	52.5 ± 10.3	0.521
WC (cm)	72.2 ± 10.0	71.0 ± 11.1	71.5 ± 31.7	0.933
BMI (kg/m ²)	21.2 ± 3.7	21.3 ± 4.1	20.8 ± 3.6	0.047
Physical activity (%)	$\textbf{0.4} \pm \textbf{0.7}$	0.6 ± 1.1	-0.2 ± 0.8	0.000
Family history				
Diabetes (%)	3.7	29.9	67.1	0.095
Obesity (%)	3.8	29.9	66.3	0.242
Hyperlipidemia (%)	3.1	31.7	65.1	0.026
Hypertension (%)	4.1	31.6	64.4	0.025
Osteoporosis (%)	3.1	33.3	63.6	0.031
Girls				
Age (y)	16.5 ± 1.1	16.7 ± 1.1	16.7 ± 1.2	0.808
Weight (kg)	57.4 ± 13.1	58.1 ± 13.9	58.1 ± 15.0	0.819
WC (cm)	74.7 ± 9.3	$\textbf{73.4} \pm \textbf{10.6}$	74.6 ± 21.2	0.435
BMI (kg/m ²)	20.7 ± 3.7	20.5 ± 3.8	20.6 ± 4.1	0.863
Physical activity (%)	0.4 ± 1.0	0.6 ± 1.2	-0.3 ± 0.7	0.000
Family history				
Diabetes (%)	6.3	29.0	64.8	0.017
Obesity (%)	5.5	27.5	67.0	0.331
Hyperlipidemia (%)	6.8	28.8	64.4	0.015
Hypertension (%)	5.3	29.6	65.2	0.150
Osteoporosis (%)	8.5	35.3	56.2	0.000

ANOVA, analysis of variance; BMI, body mass index; WC, waist circumference Sleep duration.

[†] *P*-value are resulted from ANOVA.

Results

Table 1 presents the characteristics of the study participants ages 10 to 18 y by sleep duration categories. The mean \pm SD age was 14.69 \pm 2.45 y for boys and 14.7 \pm 2.38 y for girls. No significant differences were observed between the age of participants in sleep duration categories in either group of girls and boys. In the boys group, those who slept < 5 h had lower BMI compared with participants in other two groups. However, significant differences were not observed among girls. In both groups, subjects who slept 5 to 8 h were more active. Moreover, a family history of diabetes, hypertension, high blood lipid levels, and osteoporosis among those who slept longer were higher in both sexes

The characteristics of the study participants ages 10 to 14 and 14 to 18 y by sleep duration categories are shown in the Tables 2 and 3, respectively. Among participants ages 10 to 14 y in both genders, participants who slept 5 to 8 h were more active. Among boys ages 10 to 14 y, longer sleep duration was associated with higher frequency of positive family history for diabetes, hypertension, high blood lipid levels, and osteoporosis. For girls aged 10 to 14 y, sleep duration >8 h was associated with younger age and greater family history of high blood lipid levels. For boys ages 14 to 18 y, sleep duration >8 h was related to lower BMI, greater family history of hypertension, high blood lipid levels, osteoporosis, and lower physical activity. For girls ages 14 to 18 y, sleeping >8 h was associated with lower physical activity levels, as well as with higher frequency of positive family history for diabetes, high blood lipid levels, and osteoporosis.

Clinical characteristics of all participants by age and sleep duration categories are shown in Table 4. For all participants (10-18 y), mean serum TC was positively associated with sleep duration only among boys. Moreover, in this group, those who

Mean of lipid profiles, blood pressure, serum glucose levels of participants according to sleep duration categories*: The CASPIAN-III Study

	Sleep duration (h/d)			P-value [†]
	<5	5–8	>8	
All ages 10–18 y				
Boys				
HDL (mg/dL)	46.0 ± 15.3	45.2 ± 15.6	47.0 ± 13.5	0.035
LDL (mg/dL)	$\textbf{85.4} \pm \textbf{25.7}$	87.1 ± 27.4	85.8 ± 27.1	0.608
TG (mg/dL)	94.9 ± 46.8	92.4 ± 39.7	94.9 ± 41.0	0.406
TC (mg/dL)	147.8 ± 28.9	149.1 ± 30.1	152.3 ± 32.2	0.012
FBS (mg/dL)	83.6 ± 9.5	$\textbf{86.9} \pm \textbf{19.4}$	87.1 ± 12.5	0.075
SBP (mm Hg)	101.6 ± 15.0	101.7 ± 13.3	101.4 ± 13.7	0.573
DBP (mm Hg)	64.8 ± 10.4	65.0 ± 10.5	64.8 ± 10.5	0.767
Girls				
HDL (mg/dL)	47.4 ± 15.2	44.6 ± 13.8	46.5 ± 14.7	0.237
LDL (mg/dL)	85.4 ± 25.7	87.1 ± 27.4	85.8 ± 27.1	0.608
TG (mg/dL)	95.7 ± 44.8	91.2 ± 46.4	91.5 ± 43.6	0.594
TC (mg/dL)	145.9 ± 28.7	145.7 ± 32.1	145.8 ± 32.0	0.967
FBS (mg/dL)	90.0 ± 12.1	$\textbf{87.4} \pm \textbf{13.0}$	88.6 ± 12.6	0.659
SBP (mm Hg)	103.9 ± 13.1	106.0 ± 13.3	104.4 ± 14.3	0.181
DBP (mm Hg)	67.1 ± 11.4	68.0 ± 10.5	65.8 ± 10.9	0.000
10–14 y				
Boys				
HDL (mg/dL)	43.7 ± 12.1	45.2 ± 14.5	$\textbf{47.9} \pm \textbf{14.4}$	0.002
LDL (mg/dL)	86.8 ± 22.3	84.8 ± 26.0	85.2 ± 28.0	0.902
TG (mg/dL)	$\textbf{86.8} \pm \textbf{38.2}$	91.7 ± 39.7	94.4 ± 42.7	0.116
TC (mg/dL)	147.3 ± 25.4	146.6 ± 28.4	152.5 ± 32.2	0.007
FBS (mg/dL)	$\textbf{83.3} \pm \textbf{10.1}$	$\textbf{86.7} \pm \textbf{18.9}$	$\textbf{87.3} \pm \textbf{11.7}$	0.058
SBP (mm Hg)	97.2 ± 12.1	97.2 ± 13.7	98.5 ± 13.8	0.137
DBP (mm Hg)	$\textbf{62.2} \pm \textbf{10.4}$	62.6 ± 10.9	63.2 ± 10.9	0.302
Girls				
HDL (mg/dL)	49.2 ± 16.8	46.0 ± 13.3	48.8 ± 15.0	0.198
LDL (mg/dL)	81.4 ± 24.8	96.3 ± 32.8	$\textbf{85.4} \pm \textbf{26.3}$	0.072
TG (mg/dL)	91.0 ± 42.9	88.1 ± 45.9	87.0 ± 40.1	0.458
TC (mg/dL)	149.1 ± 26.9	156.2 ± 31.1	153.1 ± 31.6	0.970
FBS (mg/dL)	91.0 ± 10.8	$\textbf{88.0} \pm \textbf{12.9}$	88.4 ± 12.2	0.383
SBP (mm Hg)	100.4 ± 10.9	101.1 ± 13.0	100.5 ± 14.3	0.737
DBP (mm Hg)	66.1 ± 11.8	65.0 ± 11.0	$\textbf{63.8} \pm \textbf{11.1}$	0.026
14–18 у				
Boys				
HDL (mg/dL)	$\textbf{48.9} \pm \textbf{18.4}$	$\textbf{45.2} \pm \textbf{16.4}$	46.2 ± 12.7	0.933
LDL (mg/dL)	84.0 ± 28.9	$\textbf{88.8} \pm \textbf{28.4}$	86.2 ± 26.4	0.559
TG (mg/dL)	103.9 ± 53.8	93.0 ± 39.7	95.3 ± 39.5	0.684
TC (mg/dL)	148.3 ± 32.5	151.1 ± 31.3	152.1 ± 32.3	0.356
FBS (mg/dL)	$\textbf{84.1} \pm \textbf{8.8}$	$\textbf{87.0} \pm \textbf{19.9}$	86.9 ± 13.2	0.489
SBP (mm Hg)	106.1 ± 16.2	105.2 ± 11.9	104.0 ± 13.1	0.055
DBP (mm Hg)	$\textbf{67.4} \pm \textbf{9.7}$	$\textbf{66.8} \pm \textbf{9.9}$	66.2 ± 9.9	0.184
Girls				
HDL (mg/dL)	44.9 ± 12.4	43.6 ± 14.1	44.4 ± 14.1	0.676
LDL (mg/dL)	83.2 ± 27.0	75.9 ± 27.1	76.5 ± 24.7	0.473
TG (mg/dL)	102.1 ± 46.9	93.6 ± 46.8	95.8 ± 46.3	0.934
TC (mg/dL)	141.1 ± 31.0	137.3 ± 30.3	139.0 ± 30.8	0.751
FBS (mg/dL)	$\textbf{88.7} \pm \textbf{13.9}$	86.9 ± 13.1	88.7 ± 13.1	0.142
SBP (mm Hg)	107.8 ± 14.3	109.9 ± 12.2	108.0 ± 13.4	0.144
DBP (mm Hg)	68.2 ± 11.0	$\textbf{70.4} \pm \textbf{9.5}$	$\textbf{67.8} \pm \textbf{10.4}$	0.002

BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride

Sleep duration.

[†] *P*-value are resulted from ANOVA.

slept >8 h had the higher mean HDL-C levels. For boys ages 10 to 14 y, similar results were found. In all age groups, girls who slept >8 h had lower mean DBP. Table 5 presents the age and multivariable adjusted associations between sleep duration and CVD risk factors. ORs for CV risk factors across categories of sleep duration are presented in Table 5. In the boys, group, there was no significant relationship between sleep duration and CVD risk factors, except for abdominal obesity. Boys who slept >8 h and 5 to 8 h had lower OR for abdominal obesity in a crude model

Table 5

ł

Odds ratio (95% Cls) for cardiovascular risk factors by categories of sleep duration* all ages 10–18 y: The CASPIAN–III Study

	Sleep duration (h/d	P-value [†]	
	5-8/<5	8>/<5	
Boys			
Overweight Model I [‡]	1 20 (0 72 - 2 66)	1 22 (0.65 2 21)	0 100
Model II [§]	1.39(0.73-2.00) 1.42(0.74-2.70)	1.23(0.05-2.31) 1.24(0.66-2.33)	0.095
Model III	1.36 (0.71–2.61)	1.13 (0/59–2.14)	0.152
Generalized obesity	. ,		
Model I [‡]	1.80 (0.70-4.60)	1.46 (0.58-3.67)	0.101
Model II ⁸	1.84 (0.72–4.71)	1.47 (0.58–3.71)	0.106
Model III Abdominal obesity	1.79 (0.69–4.62)	1.28 (0.45-3.60)	0.080
Model I [‡]	0.80 (0.43-1.50)	0.70 (0.39-1.28)	0.008
Model II [§]	0.76 (0.41–1.42)	0.69 (0.38–1.25)	0.011
Model III	0.73 (0.39–1.37)	0.68 (0.36-1.25)	0.200
Model IV [¶]	0.43 (0.19–0.95)	0.5 (0.23–1.09)	0.874
High LDL	1 10 (0 24 4 05)	0.00 (0.27, 2.00)	0.262
	1.18 (0.34-4.05)	0.89(0.27 - 2.98) 0.88(0.26 - 2.93)	0.363
Model III	1.13(0.33-3.55) 1.03(0.30-3.58)	0.88(0.20-2.33) 0.95(0.28-3.24)	0.299
Model IV [¶]	1.04 (0.30–3.61)	0.97 (0.28–3.30)	0.318
High TC			
Model I [‡]	4.23 (0.57–31.53)	6.09 (0.84-44.36)	0.058
Model II ⁸	4.19 (0.56–31.22)	6.06 (0.83-44.12)	0.056
	4.03(0.54-30.10) 4.00(0.54-20.04)	5.55(0.75-40.90) 5.63(0.76-41.56)	0.150
High TG	4.00 (0.54-23.54)	5.05 (0.70-41.50)	0.127
Model I [‡]	1.18 (0.45-3.09)	1.01 (0.40-2.58)	0.140
Model II [§]	1.18 (0.45-3.10)	1.01 (0.40-2.59)	0.141
Model III	1.10 (0.42-2.90)	1.13 (0.43–2.92)	0.458
Model IV ¹	1.09 (0.41–2.92)	1.16 (0.44–3.09)	0.655
Model I [‡]	2 79 (0 85-9 15)	2 68 (0 83-8 66)	0 389
Model II [§]	2.74 (0.83-9.00)	2.65 (0.82-8.57)	0.389
Model III	2.68 (0.81-8.82)	2.28 (0.70–7.45)	0.813
Model IV [¶]	2.67 (0.81-8.82)	2.28 (0.70-7.45)	0.826
Elevated blood pressure			
Model I [‡]	1.23(0.37-4.14) 1 17(0.25, 2.04)	1.18(0.36-3.86) 1.16(0.25, 2.70)	0.225
Model III	1.17(0.35-3.94) 1.14(0.34-3.86)	1.10(0.35-3.79) 1.14(0.34-3.78)	0.201
Model IV [¶]	1.09 (0.32–3.72)	1.14 (0.34–3.84)	0.195
Girls		. ,	
Overweight			
Model I [‡]	0.78 (0.39–1.56)	0.83 (0.43–1.61)	0.782
	0.78(0.39-1.56) 0.96(0.47-1.93)	0.83(0.43 - 1.62) 0.83(0.42 - 1.65)	0.692
General obesity	0.30 (0.47-1.33)	0.05 (0.42-1.05)	0.055
Model I [‡]	1.27 (0.44-3.65)	1.27 (0.45-3.57)	0.770
Model II [§]	1.26 (0.44-3.63)	1.28 (0.45-3.60)	0.738
Model III	1.54 (0.53–4.47)	1.14 (0.40-3.25)	0.601
Abdominal obesity	0.04 (0.40, 1.07)	0.05 (0.40, 1.95)	0 120
Model II [§]	0.94(0.48 - 1.87) 0.95(0.48 - 1.88)	0.95(0.49 - 1.85) 0.95(0.49 - 1.84)	0.129
Model III	1.11 (0.55–2.22)	1.05 (0.53-2.07)	0.559
Model IV [¶]	0.98 (0.39–2.50)	1.25 (0.51–3.11)	0.800
High LDL			
Model I [‡]	1.40 (0.41–4.79)	0.46 (0.13–1.61)	0.002
Model II ⁸	1.50 (0.43–5.20)	0.44 (0.13–1.56)	0.001
Model IV [¶]	1.36(0.37-5.05) 1.36(0.26-5.05)	0.76(0.20-2.88) 0.76(0.20-2.89)	0.008
High TC	1.50 (0.20 5.05)	0.70 (0.20 2.00)	0.000
Model I [‡]	0.65 (0.28-1.54)	0.52 (0.23-1.19)	0.065
Model II [§]	1.01 (0.30-3.48)	1.06 (0.32-3.52)	0.449
Model III	1.13 (0.32–3.94)	1.14 (0.34–3.85)	0.951
Model IV ¹	1.07 (0.31–3.73)	1.14 (0.33–3.85)	0.969
Model I [‡]	0.65(0.28-1.54)	0.52 (0.23-1.19)	0.065
Model II [§]	0.63 (0.26-1.48)	0.51 (0.22–1.18)	0.078
Model III	0.67 (0.28-1.59)	0.58 (0.25-1.36)	0.169
Model IV [¶]	0.53 (0.22-1.30)	0.53 (0.22-1.30)	0.153
		(Continued on n	ext page)

Table 5 (Continued)

	Sleep duration (h/	P-value [†]	
	5-8/<5	8>/<5	
Elevated FBS			
Model I [‡]	1.73 (0.71-4.17)	1.97 (0.83-4.67)	0.672
Model II [§]	1.73 (0.72-4.18)	1.97 (0.83-4.67)	0.678
Model III	2.03 (0.83-4.94)	2.01 (0.84-4.83)	0.588
Model IV [¶]	2.03 (0.83-4.94)	2.01 (0.84-4.83)	0.592
Elevated blood pressure			
Model I [‡]	1.29 (0.38-4.34)	1.26 (0.38-4.14)	0.624
Model II [§]	1.32 (0.39-4.47)	1.37 (0.41-4.54)	0.790
Model III	1.22 (0.36-4.17)	1.38 (0.41-4.64)	0.561
Model IV [¶]	1.18 (0.34-4.10)	1.45 (0.43-4.94)	0.559

BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; FBS, fasting blood sugar; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglyceride

CVD abnormalities following criteria, according to Adult Treatment Panel III. Criteria modified for children and adolescents: overweight: BMI; 85th–95th; obesity, BMI > 95th; low HDL: < 50 mg/dL (except in boys 15–19 y old, that cut-off was < 45 mg/dL); high LDL: > 110 mg/dL; high TG: \geq 100 mg/dL; high TC: > 200 mg/dL; elevated FBS > 100 mg/dL; high blood pressure: > 95th (adjusted by age, sex, height)

Sleep duration.

[†] *P*-value are resulted from ANOVA.

[‡] Without adjustment (crude model).

Adjusted for age.

^{||} Additionally adjusted for other characteristics including socioeconomic status, parents' educations, family history of chronic disease, sedentary lifestyle. [¶] Additionally adjusted for BMI in all abnormalities except for overweight and obesity.

(OR, 0.70; 95% CI, 0.39–1.28 and OR, 0.80; 95% CI, 0.43–1.50, respectively). Moreover, a similar result was observed in an ageadjusted model (OR, 0.69; 95% CI, 0.38–1.25 and OR, 0.76; 95% CI, 0.41–1.42, respectively).

Further adjustment for other potentially confounding variables such as socioeconomic status, parents' educations, family history of chronic disease, sedentary lifestyle, and BMI attenuated these associations. Hypercholesterolemia (LDL > 110 mg/ dL) was significantly associated with sleep duration categories only in the girls' group. Table 5 shows that participants who sleep >8 h compared with those who slept <5 h had lower OR for high LDL in a crude model (OR, 0.46; 95% CI, 0.13–1.61). OR for high LDL after control for age (model 4) was 0.44 (95% CI, 0.13–1.56) and for other confounding variable (model 5, 6) were 0.76 (95% CI, 0.20–2.88) and 0.76 (95% CI, 0.20–2.89), respectively. Conversely, compared with participants who slept <5 h, those who slept 5 to 8 h had significantly higher LDL levels in all models (crude and adjusted).

Tables 6 and 7 show sex-specific and multivariable OR of CV risk factors by categories of sleep duration and age. We found that for boys ages 10 to 14 y, there was significant inverse association (P < 0.05) between sleep duration and abdominal obesity in a crude model. These results changed substantially after adjustment for potential confounders (Table 6). Furthermore, in this group, longer sleep duration increased the risk for high TC in all models (crude and adjusted). For girls ages 10 to 14 y, participants who slept 5 to 8 h had higher risk for high LDL compared with those who slept <5 h in a crude model (P < 0.05). Conversely, participants who slept >8 h compared with those who slept <5 h had significantly lower LDL levels in a crude model. Among boys ages 14 to 18 y, there was a positive association between sleep duration and risk for abdominal obesity only in a crude model (Table 7). The girls ages 14 to 18 y who slept 5 to 8 h and >8 h had lower risk for hypercholesterolemia (LDL > 110 mg/dL) than those who slept <5 h in a crude model (Table 7).

Discussion

This study evaluated the relationship between sleep duration and CVD risk factors among school-aged children. Our findings indicate a relationship between decreased sleep duration and elevated LDL-C among all girls ages 6 to 18 y. Even after adjusting for other potential confounding variables, this association remained significant. This association also remained significant among girls ages 10 to 14 y in a crude model. Moreover, the girls ages 14 to 18 y who slept 5 to 8 h and >8 h had lower risk for hypercholesterolemia (LDL > 110 mg/dL) than those who slept <5 h in a crude model. In the current study, those (10–18 y) with sleep duration <5 h had higher risk for abdominal obesity among boys both in crude and age-adjusted models. However, this association attenuated after additional adjusting for other potential confounders. We also found a similar association among boys ages 10 to14 y only in a crude model. In contrary, long sleep duration was associated with higher risk for abdominal obesity among boys ages 14 to 18 y. Among boys ages 10 to 14 years, longer sleep duration increased the risk for high TC in all models. To the best of our knowledge, this is the first study that evaluated the association between sleep duration and CVD risk factors among a nationally representative sample of children in developing countries.

Some findings of the present study are similar to published papers [14,15] and some are different from previous studies that have examined the relationship between sleep duration and obesity, as well as CVD risk factors among children and adolescents [22–27]. We did not find a significant relationship between short sleep duration and obesity in the present study. The results of a study among American obese children and adolescents have reported that sleep duration does not predict the development of adiposity, and metabolic syndrome [12]. However, several epidemiologic studies have reported that short sleep duration is potentially related to obesity in both adults and children [7,10,28,29]. The majority of cross-sectional studies have indicated that short sleep duration (generally <6 h per night) enhances the risk for obesity in both adults and children in different countries [30]. For example, a cross-sectional study among young Iranian female students recently reported that sleep deprivation is related to lower diet quality indices and a higher rate of general and central obesity [31]. Moreover, some prospective studies have reported that short sleep duration increases weight gain and obesity risk among girls and boys [7]. However, one study has shown that long sleep duration (generally >8 h per night) is directly related to obesity [30].

The results of the present study showed that short sleep duration independent of high BMI and other confounding variables significantly increased LDL-C levels in girls. In accordance with our findings, experimental results showed that sleep deprivation elevated TC and LDL-C levels [32]. Gangwisch et al [33] reported that short sleep duration increases the risk for hypercholesterolemia in a longitudinal study among adolescents. Additionally, one study with Chinese youths has demonstrated that for each 1-h decrease in average sleep time, the risk for elevated LDL-C was 14% [9].

Several mechanisms have been proposed to explain the association of short sleep duration with obesity and hypercholesterolemia. Sleep deprivation may be associated with upregulation of appetite, energy-expenditure reduction, increasing time spent eating, and adiposity [31,34]. This association may be mediated by decreasing levels of leptin, increasing levels of ghrelin, an increased ratio of ghrelin to leptin, low levels of testosterone, and high amounts of evening cortisol levels [35–39].

Odds ratio (95% Cls) for cardiovascular risk factors by categories of sleep duration* ages 10-14 y: The CASPIAN-III Study

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Sleep duration (h/d)		<i>P</i> -value [†]
Jergs Overweight Overweight<		5-8/<5	8>/<5	
Overwight Model II ⁺ 0.77 (0.44–1.34) 0.70 (0.41–1.19) 0.229 Model III ⁺ 1.23 (0.51–2.97) 1.01 (0.42–2.43) 0.334 Ceneralized obesity 0.70 (0.41–1.9) 0.316 0.3372 Model III ⁺ 0.23 (0.51–2.97) 1.01 (0.42–2.43) 0.3272 Adcominal obesity 0.33 (0.42–1.74) 0.75 (0.32–1.64) 0.2259 Model III ⁺ 0.46 (0.47–5.72) 1.12 (0.32–3.85) 0.022.53 Model III ⁺ 0.46 (0.24–0.54) 0.42 (0.21–1.61) 0.570 Model III ⁺ 0.45 (0.23–0.54) 0.42 (0.21–1.61) 0.884 Model III ⁺ 0.46 (0.24–0.54) 0.42 (0.21–1.61) 0.877 Model III ⁺ 0.47 (0.24–0.57) 0.384 0.001 0.011 Model III ⁺ 0.47 (0.24–0.57) 0.261 0.071 0.014 Model III ⁺ 0.47 (0.24–0.57) 0.262 0.014 0.014 Model III ⁺ 0.47 (0.24–0.57) 0.261 0.014 0.014 Model III ⁺ 1.47 (0.32–6.73) 1.34 (0.32–5.64) 0.272 0.	Boys			
Model IF 0.77 (0.44-1.34) 0.70 (0.41-1.9) 0.299 Model IIF 1.23 (0.51-2.97) 1.01 (0.42-2.43) 0.534 Model IIF 1.23 (0.51-2.97) 1.01 (0.42-2.43) 0.372 Model IIF 0.36 (0.51-2.97) 1.01 (0.42-2.43) 0.372 Model IIF 0.45 (0.42-1.74) 0.75 (0.38-1.46) 0.029 Model IVI 0.45 (0.24-0.75) 0.42 (0.11-0.16) 0.570 Model IVI 0.45 (0.24-0.84) 0.42 (0.21-0.16) 0.570 Model IVI 0.45 (0.24-0.84) 0.42 (0.21-0.16) 0.884 Model IVI 0.42 (0.23-1.63) 0.42 (0.21-0.16) 0.884 Model IVI 0.62 (0.23-1.63) 0.42 (0.21-0.16) 0.884 Model IVI 0.42 (0.00) 1.10 (0.00) 0.011 Model IVI 4.494 (0.00) 1.14 (0.00) 0.014 Model IVI 4.408 (0.00) 1.12 (0.00) 0.013 Model IVI 4.408 (0.200 1.10 (0.00) 0.014 Model IVI 1.47 (0.22-6.73) 1.54 (0.33-6.74) 0.528 Evertue	Överweight			
Model III ¹ 1.21 (0.51-297) 1.01 (0.42-2.43) 0.534 Model II ¹ 0.77 (0.44-1.34) 0.70 (0.41-1.19) 0.316 Model II ¹⁰ 1.23 (0.51-297) 1.01 (0.42-2.43) 0.372 Andominal obesity 0.75 (0.38-1.46) 0.022 0.022 Model II ¹⁰ 1.64 (0.47-5.72) 1.12 (0.23-23.85) 0.239 Model II ¹⁰ 0.39 (0.10-1.54) 0.42 (0.11-1.61) 0.570 Model II ¹¹ 0.652 (0.21-1.33) 0.454 (0.21-1.34) 0.42 (0.11-1.61) 0.8377 Model II ¹¹ 0.49 (0.00) 1.34 (0.00) 0.001 Model II ¹¹ 0.877 Model II ¹¹ 4.94 (0.00) 1.34 (0.00) 0.014 Model II ¹¹ 0.877 Model II ¹¹ 4.94 (0.00) 1.34 (0.00) 0.014 Model II ¹¹ 0.52 Model II ¹¹ 4.97 (0.31-2.65) 0.54 (0.23-2.26) 0.752 Model II ¹¹ 1.47 (0.32-6.73) 1.54 (0.35-6.31) 0.552 Model II ¹¹ 1.48 (0.34-8.21) 1.81 (0.38-8.74) 0.552 Model II ¹¹ 1.28 (0.57-4.65)	Model I [‡]	0.77 (0.44–1.34)	0.70 (0.41-1.19)	0.209
Generalized obesity 0.77 (0.44–1.34) 0.70 (0.41–1.19) 0.316 Model III ^{II} 0.23 (0.51–2.97) 1.01 (0.42–2.43) 0.372 Model III ^{II} 0.85 (0.42–1.74) 0.75 (0.81–1.46) 0.022 Model III ^{II} 0.16 (0.42–0.75) 1.12 (0.32–3.85) 0.259 Model IV ^{II} 0.91 (0.10–5.41) 0.42 (0.23–0.75) 0.368 Model IV ^{II} 0.45 (0.24–0.84) 0.42 (0.23–0.75) 0.368 Model IV ^{II} 0.93 (0.10–1.54) 0.42 (0.23–0.75) 0.368 Model IV ^{II} 0.93 (0.10–1.54) 0.42 (0.23–0.75) 0.368 Model IV ^{II} 0.93 (0.10–1.54) 0.42 (0.21–1.39) 0.884 Model IV ^{II} 0.93 (0.10–1.54) 0.42 (0.11–1.61) 0.75 (0.25 (0.11–1.61) Model IV ^{II} 1.14 (0.00) 1.12 (0.00) 0.011 Model IV ^{II} 1.47 (0.32–6.73)	Model III [§]	1.23 (0.51–2.97)	1.01 (0.42-2.43)	0.534
Model I ⁱ 0.70 (0.41-1.9) 0.316 Model I ⁱⁱ 1.23 (0.51-2.97) 101 (0.42-2.43) 0.372 Aldominal obesity	Generalized obesity			
Model III 1.23 (0.51-2.97) 1.01 (0.42-2.43) 0.372 Abdomial obesity 0.75 (0.43-2.43) 0.239 Model III 0.68 (0.42-1.74) 0.75 (0.33-1.46) 0.022 Model IIII 0.68 (0.42-1.74) 0.74 (0.32-3.83) 0.239 Model IV 0.33 (0.10-1.54) 0.42 (0.23-0.75) 0.368 Model IV 0.05 (0.22-1.63) 0.24 (0.21-1.39) 0.884 Model IV 0.39 (0.10-1.54) 0.42 (0.23-0.75) 0.368 Model IV 0.39 (0.10-1.54) 0.42 (0.01-1.61) 0.871 Model IV 0.39 (0.10-1.54) 0.42 (0.21-1.39) 0.884 Model IV 0.39 (0.10-1.54) 0.42 (0.21-1.39) 0.872 Model III 0.41 (0.00) 1.10 (0.00) 0.011 Model III 0.41 (0.00) 1.11 (0.00) 0.011 Model IV 0.42 (0.32-2.28) 0.372 (0.44-2.567) 0.252 Model IV 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.252 Model IV 2.99 (0.38-2.285) 3.37 (0.44-2.567) 0.250 Model IV	Model I [‡]	0.77 (0.44–1.34)	0.70 (0.41–1.19)	0.316
Abdominal obesity 0021 Model II ^{II} 1.64 (0.47-5.72) 1.12 (0.32-3.85) 0.259 Model II ^{II} 0.64 (0.11-1.61) 0.570 0.383 (0.10-1.54) 0.42 (0.11-1.61) 0.570 High LDL 0.42 (0.11-1.61) 0.870 0.884 Model II ^{II} 0.62 (0.22-0.63) 0.54 (0.21-1.39) 0.884 Model II ^{II} 0.63 (0.10-1.54) 0.42 (0.11-1.61) 0.877 High TC 0.39 (0.10-1.54) 0.42 (0.00) 0.011 Model II ^{II} 4.94 (0.00) 1.10 (0.00) 0.013 0.001 Model II ^{II} 0.752 (0.33-2.28) 0.752 Model II ^{II} 0.79 (0.31-2.05) 0.94 (0.39-2.28) 0.752 0.052 Model II ^{II} 1.47 (0.32-6.73) 1.54 (0.33-6.81) 0.528 0.652 Elevated Fils 0.528 0.652 0.258 Elevated Fils 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 0.333 0.282 Model II ^{III} 1.52 (0.57-4.05) 1.69 (0.44	Model III ⁸	1.23 (0.51–2.97)	1.01 (0.42–2.43)	0.372
Model I ^{II} 0.85 (0.42-1.74) 0.75 (0.33-1.46) 0.022 Model I ^{VI} 0.39 (0.10-1.54) 0.42 (0.11-1.61) 0.570 High IDL	Abdominal obesity			
Model IV 1.14 (0.47-5.22) 1.12 (0.22-3.85) 0.259 Model IV 0.39 (0.10-1.54) 0.42 (0.11-1.51) 0.570 Model IV 0.45 (0.24-0.84) 0.42 (0.21-1.39) 0.388 Model IV 0.50 (0.23-1.62) 0.54 (0.21-1.39) 0.884 Model IV 0.30 (0.10-1.54) 0.42 (0.11-1.51) 0.877 High TC	Model I [‡]	0.85 (0.42–1.74)	0.75 (0.38–1.46)	0.022
Model (V 0.39 (0.10-1.54) 0.42 (0.23-0.75) 0.368 Model II ¹ 0.45 (0.24-0.84) 0.42 (0.23-0.75) 0.368 Model II ¹ 0.63 (0.10-1.54) 0.24 (0.21-1.39) 0.884 Model IV 0.30 (0.10-1.54) 0.24 (0.21-1.39) 0.884 Model IV 0.30 (0.10-1.54) 0.42 (0.23-0.75) 0.93 (0.10-1.54) Model II ¹ 4.14 (0.00) 1.10 (0.00) 0.014 Model II ¹ 4.11 (0.00) 1.10 (0.00) 0.014 Model II ¹ 4.11 (0.00) 1.10 (0.00) 0.014 Model II ¹ 1.47 (0.22-6.73) 1.94 (0.39-2.28) 0.752 Model II ¹ 1.47 (0.22-6.73) 1.54 (0.35-6.81) 0.652 Model II ¹ 1.47 (0.22-6.73) 1.54 (0.35-6.43) 0.282 Model II ¹¹ 1.46 (0.34-8.21) 1.81 (0.38-8.74) 0.282 Model II ¹¹ 1.45 (0.57-4.05) 1.67 (0.44-2.567) 0.290 Model II ¹¹ 1.52 (0.57-4.05) 0.74 (0.22-5.22) 0.903 Model II ¹¹ 1.52 (0.57-4.05) 0.74 (0.22-3.22) 0.9	Model III ³	1.64 (0.47–5.72)	1.12(0.32-3.85)	0.259
High LDL Model IF 0.45 (0.24-0.84) 0.42 (0.23-0.75) 0.358 Model IF 0.62 (0.23-1.63) 0.54 (0.21-1.39) 0.884 Model IV 0.39 (0.10-1.54) 0.42 (0.11-1.61) 0.877 High TC		0.39 (0.10-1.54)	0.42 (0.11-1.61)	0.570
Model III 0.53 (0.24-0.54) 0.24 (0.25-0.53) 0.036 Model IVI 0.39 (0.10-1.54) 0.24 (0.21-1.39) 0.884 Model IVI 0.39 (0.10-1.54) 0.24 (0.21-1.39) 0.884 Model IVI 4.94 (0.00) 1.34 (0.00) 0.001 Model IVI 4.94 (0.00) 1.10 (0.00) 0.011 Model IVI 4.98 (0.00) 1.10 (0.00) 0.013 High TC 0.79 (0.31-2.05) 0.94 (0.39-2.28) 0.752 Model IVI 1.47 (0.32-6.73) 1.54 (0.35-6.81) 0.652 Model IVI 1.68 (0.34-8.21) 1.81 (0.38-8.74) 0.528 Elevated FBS 0.55 (0.17-2.45) 1.69 (0.66-4.33) 0.282 Model IVI 2.96 (0.38-22.95) 3.67 (0.44-25.67) 0.285 Elevated BS 0.55 (0.17-2.45) 0.74 (0.22-2.52) 0.903 Model IVI 2.96 (0.38-22.85) 3.67 (0.44-2.567) 0.285 Elevated BS 0.55 (0.17-2.45) 0.74 (0.22-2.52) 0.903 Model IVI 3.42 (0.00) 4.42 (0.00) 0.331 <td< td=""><td></td><td>0.45 (0.24, 0.94)</td><td>0.42 (0.22, 0.75)</td><td>0.200</td></td<>		0.45 (0.24, 0.94)	0.42 (0.22, 0.75)	0.200
Nodel III 0.02 (0.23-1.03) 0.4 (0.21-1.59) 0.04 (0.21-1.59) 0.04 (0.21-1.59) Model IV 0.39 (0.01-0.154) 0.42 (0.11-1.51) 0.877 Model IV 4.94 (0.00) 1.34 (0.00) 0.01 Model IV 4.08 (0.00) 1.10 (0.00) 0.014 Model IV 4.08 (0.00) 1.12 (0.00) 0.013 Model IV 1.48 (0.31-2.05) 0.94 (0.39-2.28) 0.752 Model IV 1.47 (0.32-6.73) 1.54 (0.35-6.81) 0.552 Model IV 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 Model IV 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 Model IV 2.24 (0.38-2.2.85) 3.67 (0.44-2.5.67) 0.285 Model IV 2.24 (0.03-2.2.5) 3.67 (0.44-2.5.67) 0.285 Model IV 3.55 (0.00) 4.42 (0.00) 0.381 Model IV 3.42 (0.00) 4.46 (0.00) 0.333 Grits 0 0.74 (0.22-2.52) 0.903 Model IV 3.42 (0.00) 4.48 (0.00.316) 0.766 Model	Model II ⁸	0.45(0.24-0.84)	0.42(0.23-0.75)	0.308
model N bbs (b(16-1.4f) bbs (b(17-1.4f) bbs (b(17-1.4f) <thbs (b(17-1.4f)<="" th=""></thbs>	Model IV	0.02(0.25-1.05) 0.39(0.10-1.54)	0.34(0.21-1.39) 0.42(0.11-1.61)	0.864
Instruct 4.94 (0.00) 1.34 (0.00) 0.001 Model II ¹ 4.11 (0.00) 1.10 (0.00) 0.014 Model IV ¹¹ 4.08 (0.00) 1.12 (0.00) 0.014 Model IV ¹¹ 0.79 (0.31-2.05) 0.94 (0.39-2.28) 0.752 Model IV ¹¹ 1.47 (0.32-6.73) 1.54 (0.35-6.81) 0.652 Model IV ¹¹ 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 Model IV ¹¹ 2.96 (0.38-22.99) 3.37 (0.44-25.67) 0.280 Model IV ¹¹ 2.96 (0.38-22.85) 3.67 (0.44-25.67) 0.285 Elevated Bood pressure 0.46 (0.00) 0.381 Model II ¹¹ 3.55 (0.00) 4.42 (0.00) 0.381 Model II ¹¹ 3.55 (0.00) 4.42 (0.00) 0.381 Model II ¹¹ 3.52 (0.00) 4.48 (0.00) 0.337 Cirits 0 0.076 0.076 Model II ¹¹ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.667 Model II ¹¹ 1.53 (0.58-4.02) 0.98 (0.32-2.96) 0.333 General o	High TC	0.55 (0.10-1.54)	0.42 (0.11-1.01)	0.077
Model III ¹ 4.11 (0.00) 1.01 (0.00) 0.014 Model IV ¹ 4.08 (0.00) 1.12 (0.00) 0.013 High TG	Model I [‡]	494(000)	1 34 (0 00)	0.001
Model IVI 4.08 (0.00) 1.12 (0.00) 0.013 High TG	Model III [§]	4 11 (0.00)	1 10 (0.00)	0.014
High TG High TG High TG Model II ⁴ 0.79 (0.31-2.05) 0.94 (0.39-2.28) 0.752 Model III ⁴ 1.47 (0.32-6.73) 1.54 (0.35-6.81) 0.652 Model III ⁴ 1.68 (0.34-8.21) 1.81 (0.38-8.74) 0.528 Blevated FBS 0.96 (0.66-4.33) 0.282 Model II ¹¹ 2.96 (0.38-22.99) 3.37 (0.44-25.67) 0.290 Model II ¹¹ 2.96 (0.38-22.85) 3.67 (0.44-25.67) 0.285 Elevated blood pressure 0.65 (0.17-2.45) 0.74 (0.22-2.52) 0.903 Model II ¹¹ 3.55 (0.00) 4.42 (0.00) 0.347 Girls 3.74 (0.79-3.81) 1.48 (0.70-3.16) 0.867 Model IV ¹¹ 1.40 (0.45-4.32) 0.98 (0.32-2.96) 0.311 Model II ¹¹ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.867 Model II ¹¹ 1.40 (0.45-4.32) 0.98 (0.32-2.96) 0.311 Model II ¹¹ 1.53 (0.58-4.08) 1.21 (0.47-3.09) 0.131 Model II ¹¹ 1.56 (0.34-7.15) 0.80 (0.18	Model IV ^{II}	4.08 (0.00)	1.12 (0.00)	0.013
Model If 0.79 (0.31-2.05) 0.94 (0.33-2.28) 0.752 Model IVI 1.47 (0.32-6.73) 1.54 (0.35-6.81) 0.652 Model IVI 1.68 (0.34-8.21) 1.81 (0.35-6.81) 0.652 Model IVI 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 Model IVI 2.96 (0.38-22.99) 3.37 (0.44-25.67) 0.290 Model IVI 2.96 (0.38-22.95) 3.67 (0.44-25.67) 0.285 Elevated blood pressure 0.65 (0.17-2.45) 0.74 (0.22-2.52) 0.903 Model IVI 3.55 (0.00) 4.42 (0.00) 0.381 Model IVI 3.52 (0.00) 4.42 (0.00) 0.381 Model IVI 3.42 (0.00) 4.46 (0.00) 0.347 Grits 0 0.98 (0.32-2.96) 0.333 General obesity 1 1.48 (0.70-3.16) 0.766 Model IVI 1.29 (0.36-4.62) 1.71 (0.34-4.09) 0.379 Model IVI 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.379 Model IVI 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.379 Model IVI	High TG	100 (000)	1112 (0100)	01010
Model III 1.47 (0.32-6.73) 1.54 (0.35-6.81) 0.652 Model IVI 1.68 (0.34-8.21) 1.81 (0.38-8.74) 0.528 Elevated FBS	Model I [‡]	0.79 (0.31-2.05)	0.94(0.39-2.28)	0.752
Model IVI 1.68 (0.34-8.21) 1.81 (0.38-8.74) 0.528 Elevated FBS	Model III [§]	1.47 (0.32–6.73)	1.54 (0.35–6.81)	0.652
Elevated FBS 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 Model II ¹¹ 2.96 (0.38-22.99) 3.37 (0.44-25.67) 0.290 Model IV ¹¹ 2.94 (0.38-22.85) 3.67 (0.44-25.67) 0.285 Elevated Iblood pressure 0.65 (0.17-2.45) 0.74 (0.22-2.52) 0.903 Model IV ¹¹ 3.55 (0.00) 4.42 (0.00) 0.341 Model IV ¹¹ 3.55 (0.00) 4.42 (0.00) 0.347 Girds 0 0.938 (0.22-2.96) 0.333 Overweight 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.867 Model I ¹¹ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model I ¹¹ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model I ¹¹ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model I ¹¹ 1.56 (0.34-7.15) 0.80 (0.18-3.59) 0.200 Model I ¹¹ 1.56 (0.34-7.15) 0.80 (0.18-3.59) 0.200 Model I ¹¹¹ 1.56 (0.34-7.15) 0.80 (0.18-3.59) 0.200 Model I ¹¹¹ 1.29 (0.36-4.62) 1.17 (0.34-4.09) <	Model IV ^{II}	1.68 (0.34-8.21)	1.81 (0.38-8.74)	0.528
Model I ⁱ 1.52 (0.57-4.05) 1.69 (0.66-4.33) 0.282 Model II ⁱ 2.96 (0.38-22.99) 3.37 (0.44-25.67) 0.290 Model IV ⁱ 2.94 (0.38-22.85) 3.67 (0.44-25.67) 0.285 Elevated blood pressure	Elevated FBS	· · · ·	`````	
Model III ⁱⁱ 2.96 (0.38-22.95) 3.37 (0.44-25.67) 0.290 Model IV ⁱⁱ 2.90 (0.38-22.85) 3.67 (0.44-25.67) 0.285 Elevated blood pressure	Model I [‡]	1.52 (0.57-4.05)	1.69 (0.66-4.33)	0.282
Model IVI 2.94 (0.38-22.85) 3.67 (0.44-25.67) 0.285 Elevated blood pressure	Model III [§]	2.96 (0.38-22.99)	3.37 (0.44-25.67)	0.290
Elevated blood pressure Model II ⁴ 0.65 (0.17-2.45) 0.74 (0.22-2.52) 0.903 Model II ⁴ 3.55 (0.00) 4.42 (0.00) 0.381 Model IV ⁴ 3.42 (0.00) 4.46 (0.00) 0.347 Girls 0.993 (0.347) Overweight 0.867 Model II ⁶ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.867 Model II ⁶ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model II ⁶ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model II ⁶ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model II ⁶ 1.53 (0.58-4.08) 1.21 (0.47-3.09) 0.111 Abdominal obesity Model II ⁶ 1.53 (0.58-4.08) 1.21 (0.47-3.09) 0.131 Model II ⁶ 1.52 (0.58-4.02) 1.17 (0.34-4.09) 0.979 High DL 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 Model IV ¹ 1.29 (0.36-4.62) 0.99 (0.36-2.72) 0.224 <	Model IV ^{II}	2.94 (0.38-22.85)	3.67 (0.44-25.67)	0.285
Model IF 0.65 (0.17–2.45) 0.74 (0.22–2.52) 0.903 Model IVF 3.55 (0.00) 4.42 (0.00) 0.381 Model IVF 3.42 (0.00) 4.46 (0.00) 0.347 Girls 4.46 (0.00) 0.347 Overweight 0.867 Model IF 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.867 Model IF 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.333 General obesity 0.903 (0.32–2.96) 0.311 Model IF 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.706 Model IF 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.111 Abominal obesity 1.48 (0.70–3.16) 0.706 Model IF 1.53 (0.58–4.08) 1.21 (0.47–3.09) 0.131 Model IF 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.979 High LDL 0.99 (0.54–1.81) 0.007 Model IF 1.46 (0.78–2.74) 0.99 (0.54–2.72) 0.224	Elevated blood pressure			
Model III ⁶ 3.55 (0.00) 4.42 (0.00) 0.381 Model IV ¹ 3.42 (0.00) 4.46 (0.00) 0.347 Girls 0.927 Overweight 0.867 Model II ⁶ 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.867 Model II ⁶ 1.40 (0.45–4.32) 0.99 (0.32–2.96) 0.333 General obesity 0.706 Model II ⁶ 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.706 Model II ⁶ 1.74 (0.79–3.81) 0.80 (0.18–3.59) 0.111 Abdominal obesity 0.998 (0.32–2.96) 0.111 Abdominal obesity 0.200 0.311 0.200 Model I ¹⁶ 1.56 (0.34–7.15) 0.80 (0.18–3.59) 0.200 0.979 High DL 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.979 High TC 1.29 (0.36–1.245) 0.99 (0.36–2.72) 0.224 Model IV ¹⁰ 1.29 (0.36–1.246) 2.88 (0.69–12.10) 0.266	Model I [‡]	0.65 (0.17-2.45)	0.74 (0.22-2.52)	0.903
Model IVI 3.42 (0.00) 4.46 (0.00) 0.347 Girls	Model III [§]	3.55 (0.00)	4.42 (0.00)	0.381
Girls Overweight 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.867 Model II ⁴ 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.333 General obesity	Model IV	3.42 (0.00)	4.46 (0.00)	0.347
Overweight 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.83 Model I [‡] 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.333 General obesity Model II [‡] 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.706 Model II [‡] 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.706 Model III [‡] 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.111 Abdominal obesity Model II [‡] 1.53 (0.58–4.08) 1.21 (0.47–3.09) 0.131 Model III [§] 1.56 (0.34–7.15) 0.80 (0.18–3.59) 0.200 Model IV ⁰ 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.979 High LDL 1.54 (0.55–4.25) 0.99 (0.54–1.81) 0.007 Model IV ⁰ 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 2.85 (0.65–12.46) 2.88 (0.69–12.10) 0.266 Model I [‡] 2.33 (0.29–18.52) 2.14 (0.27–16.60) 0.762 Model I [‡]	Girls			
Model II ⁶ 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.867 Model III ⁶ 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.333 General obesity	Overweight			
Model III ⁶ 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.333 General obesity	Model I [‡]	1.74 (0.79–3.81)	1.48 (0.70-3.16)	0.867
General obesity Model I ⁴ 1.74 (0.79-3.81) 1.48 (0.70-3.16) 0.706 Model II ⁴ 1.40 (0.45-4.32) 0.98 (0.32-2.96) 0.111 Abdominal obesity	Model III ⁸	1.40 (0.45-4.32)	0.98 (0.32–2.96)	0.333
Model II ⁶ 1.74 (0.79–3.81) 1.48 (0.70–3.16) 0.706 Model III ⁶ 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.111 Abdominal obesity	General obesity			0.700
Model III ⁵ 1.40 (0.45–4.32) 0.98 (0.32–2.96) 0.111 Abdominal obesity	Model I [‡]	1.74 (0.79–3.81)	1.48 (0.70-3.16)	0.706
Addominal obesity Model I [‡] 1.53 (0.58-4.08) 1.21 (0.47-3.09) 0.131 Model III [§] 1.56 (0.34-7.15) 0.80 (0.18-3.59) 0.200 Model IV ^{II} 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.979 High LDL 0.007 0.064 [1I [§] 0.007 Model IV ^{II} 1.54 (0.55-4.25) 0.99 (0.36-2.72) 0.224 Model IV ^{II} 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.99 (0.36-2.72) 0.224 Model IV ^{II} 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.99 (0.36-2.72) 0.224 Model IV ^{II} 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.33 (0.29-18.52) 2.14 (0.27-16.60) 0.762 Model IV ^{II} 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model III [§] 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model III [§] 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 <	Model III [®]	1.40 (0.45–4.32)	0.98 (0.32-2.96)	0.111
Model I ⁴ 1.53 (0.34–0.65) 1.21 (0.47–5.09) 0.131 Model III ⁸ 1.56 (0.34–7.15) 0.80 (0.18–3.59) 0.200 Model IV ^{II} 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.979 High LDL 0.99 (0.54–1.81) 0.007 Model IV ^{II} 1.54 (0.55–4.25) 0.99 (0.36–2.72) 0.224 Model IV ^{II} 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 2.85 (0.65–1.2.46) 2.88 (0.69–12.10) 0.266 Model IV ^{II} 2.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 2.85 (0.65–12.46) 2.88 (0.69–12.10) 0.266 Model IV ^{II} 2.24 (0.28–17.93) 2.23 (0.28–17.48) 0.630 High TG 2.24 (0.28–17.93) 2.23 (0.28–17.48) 0.630 Model II ^{II} 0.91 (0.18–4.49) 0.71 (0.15–3.47) 0.537 Elevated FBS 0.86 (0.43–1.70) 0.91 (0.48–1.73) 0.597		1 52 (0 58 4 08)	1 21 (0 47 2 00)	0 1 2 1
Model II ^{1/2} 1.36 (0.34-7.15) 0.30 (0.18-5.35) 0.200 Model IV ¹¹ 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.979 High LDL Model I ¹⁵ 1.46 (0.78-2.74) 0.99 (0.54-1.81) 0.007 Model IV ¹¹ 1.54 (0.55-4.25) 0.99 (0.36-2.72) 0.224 Model IV ¹¹ 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.90 (0.36-2.72) 0.224 Model IV ¹¹ 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.90 (0.36-2.72) 0.224 Model IV ¹¹ 2.90 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.91 (0.27-16.60) 0.762 Model IV ¹¹ 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model II ¹⁵ 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS 0.91 (0.48-1 73) 0.99	Model II ⁸	1.53 (0.58-4.08)	1.21(0.47-3.09)	0.131
High LDL 1.25 (0.36-4.32) 1.17 (0.34-4.33) 0.373 High LDL Model I [‡] 1.46 (0.78-2.74) 0.99 (0.54-1.81) 0.007 Model II [§] 1.54 (0.55-4.25) 0.99 (0.36-2.72) 0.224 Model IV ^{II} 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.007 0.061 IV ^{II} 0.266 Model IV ^{II} 2.85 (0.65-12.46) 2.88 (0.69-12.10) 0.266 Model III [§] 2.33 (0.29-18.52) 2.14 (0.27-16.60) 0.762 Model IV ^{II} 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model III [§] 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model III [§] 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS Model I [‡] 0.86 (0.43-1.70) 0.91 (0.48-1.73) 0.990	Model IV	1.30 (0.34-7.13)	(0.00 (0.16 - 5.59)) 1 17 (0 34 - 4 09)	0.200
Might DD Model I ¹⁶ 1.46 (0.78–2.74) 0.99 (0.54–1.81) 0.007 Model III ⁸ 1.54 (0.55–4.25) 0.99 (0.36–2.72) 0.224 Model IV ^{II} 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 0.99 (0.54–1.81) 0.007 Model IV ^{II} 1.29 (0.36–4.62) 1.17 (0.34–4.09) 0.200 High TC 0.99 (0.54–1.81) 0.200 Model IV ^{II} 2.98 (0.65–12.46) 2.88 (0.69–12.10) 0.266 Model III ⁸ 2.33 (0.29–18.52) 2.14 (0.27–16.60) 0.762 Model IV ^{II} 2.24 (0.28–17.93) 2.23 (0.28–17.48) 0.630 High TG 0.90 (0.37–2.45) 0.59 (0.24–1.45) 0.070 Model II ¹⁶ 0.96 (0.37–2.45) 0.59 (0.24–1.45) 0.070 0.466 Model II ¹⁶ 0.91 (0.18–4.49) 0.71 (0.15–3.47) 0.537 Elevated FBS 0.86 (0.43–1.70) 0.91 (0.48–1.73) 0.99	High I DI	1.29 (0.30-4.02)	1.17 (0.54-4.05)	0.979
Model III ⁶ 1.54 (0.55-4.25) 0.99 (0.36-2.72) 0.224 Model IV ^{II} 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 0.99 (0.36-2.72) 0.224 Model III ⁶ 2.85 (0.65-12.46) 2.88 (0.69-12.10) 0.266 Model III ⁶ 2.33 (0.29-18.52) 2.14 (0.27-16.60) 0.762 Model IV ^{II} 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model III ⁶ 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model III ⁶ 0.91 (0.48-173) 0.537 Elevated FBS 0.86 (0.43-170) 0.91 (0.48-173) 0.909	Model I [‡]	1 46 (0 78-2 74)	0.99(0.54 - 1.81)	0.007
Model IVI 1.29 (0.36-4.62) 1.17 (0.34-4.09) 0.200 High TC 1.17 (0.34-4.09) 0.200 Model I [‡] 2.85 (0.65-12.46) 2.88 (0.69-12.10) 0.266 Model III [§] 2.33 (0.29-18.52) 2.14 (0.27-16.60) 0.762 Model IVI 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG 1.22 (0.26-5.71) 0.59 (0.24-1.45) 0.070 Model I [‡] 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model IVI 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS Model I [‡] 0.86 (0.43-1.70) 0.91 (0.48-1.73) 0.990	Model III [§]	1.40(0.70(2.74)) 1 54 (0 55–4 25)	0.99(0.34-1.01)	0.007
High TC 1.25 (0.55 + 1.2) 1.17 (0.5 + 1.05) 0.266 Model I [‡] 2.85 (0.65 - 12.46) 2.88 (0.69 - 12.10) 0.266 Model III [§] 2.33 (0.29 - 18.52) 2.14 (0.27 - 16.60) 0.762 Model IV ^{II} 2.24 (0.28 - 17.93) 2.23 (0.28 - 17.48) 0.630 High TG 1.22 (0.26 - 5.71) 0.59 (0.24 - 1.45) 0.070 Model IV ^{II} 0.91 (0.18 - 4.49) 0.71 (0.15 - 3.47) 0.537 Elevated FBS Model I [‡] 0.86 (0.43 - 1.70) 0.91 (0.48 - 1.73) 0.990	Model IV	1.29(0.36-4.62)	1 17 (0 34 - 4 09)	0.221
Model I [‡] 2.85 (0.65-12.46) 2.88 (0.69-12.10) 0.266 Model III [§] 2.33 (0.29-18.52) 2.14 (0.27-16.60) 0.762 Model IV ^{II} 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model II [§] 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model IV ^{III} 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS 0.86 (0.43-1.70) 0.91 (0.48-1.73) 0.990	High TC	1.23 (0.50 1.62)	1.17 (0.51 1.05)	0.200
Model III [§] 2.33 (0.29-18.52) 2.14 (0.27-16.60) 0.762 Model IV ^{II} 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG	Model I [‡]	285 (065-1246)	2.88 (0.69-12.10)	0 266
Model IVII 2.24 (0.28-17.93) 2.23 (0.28-17.48) 0.630 High TG	Model III [§]	2.33 (0.29–18.52)	2.14 (0.27–16.60)	0.762
High TG 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model II [§] 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model IV ^{II} 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS 0.86 (0.43-1.70) 0.91 (0.48-1.73) 0.999	Model IV	2.24 (0.28–17.93)	2.23 (0.28–17.48)	0.630
Model I [‡] 0.96 (0.37-2.45) 0.59 (0.24-1.45) 0.070 Model III [§] 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model IV ^{II} 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS 0.86 (0.43-1.70) 0.91 (0.48-1.73) 0.99	High TG	``	````	
Model III [§] 1.22 (0.26-5.71) 0.62 (0.13-2.90) 0.146 Model IV ^{II} 0.91 (0.18-4.49) 0.71 (0.15-3.47) 0.537 Elevated FBS 0.86 (0.43-1.70) 0.91 (0.48-1.73) 0.990	Model I [‡]	0.96 (0.37-2.45)	0.59 (0.24–1.45)	0.070
Model IVII 0.91 (0.18–4.49) 0.71 (0.15–3.47) 0.537 Elevated FBS 0.86 (0.43–1.70) 0.91 (0.48–1.73) 0.990	Model III [§]	1.22 (0.26-5.71)	0.62 (0.13-2.90)	0.146
Elevated FBS Model I [±] 0.86 (0.43–1.70) 0.91 (0.48–1.73) 0.990	Model IV ^{II}	0.91 (0.18-4.49)	0.71 (0.15-3.47)	0.537
Model I [‡] 0.86 (0.43–1.70) 0.91 (0.48–1.73) 0.900	Elevated FBS			
0.00 (0.10 1.10) 0.01 (0.10 1.10) 0.000	Model I [‡]	0.86 (0.43-1.70)	0.91 (0.48-1.73)	0.999
Model III [§] 1.37 (0.44-4.27) 1.01 (0.33-3.07) 0.423	Model III [§]	1.37 (0.44-4.27)	1.01 (0.33-3.07)	0.423
Model IVII 1.30 (0.42-4.08) 0.92 (0.30-2.83) 0.323	Model IV	1.30 (0.42-4.08)	0.92 (0.30-2.83)	0.323
Elevated blood pressure	Elevated blood pressure			
Model I ⁺ 0.62 (0.19–2.02) 0.60 (0.20–1.78) 0.487	Model I [‡]	0.62 (0.19-2.02)	0.60 (0.20-1.78)	0.487
Model III 0.63 (0.07-5.45) 0.97 (0.12-7.87) 0.539	Model III [§]	0.63 (0.07–5.45)	0.97 (0.12–7.87)	0.539
Model IV ^{II} 0.57 (0.06–4.96) 0.94 (0.12–7.64) 0.481	Model IV	0.57 (0.06–4.96)	0.94 (0.12–7.64)	0.481

ANOVA, analysis of variance; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; FBS, fasting blood sugar; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglyceride

CVD abnormalities following criteria, according to Adult Treatment Panel III. Criteria modified for children and adolescents: overweight: BMI; $85^{th}-95^{th}$; obesity, BMI > 95^{th}; low HDL: < 50 mg/dL (except in boys 15–19 y old, that cut-off was < 45 mg/dL); high LDL: > 110 mg/dL; high TG: > 100 mg/dL; high TC: > 200 mg/dL; elevated FBS > 100 mg/dL; high blood pressure: > 95^{th} (adjusted by age, sex, height)

Sleep duration.

[†] *P*-value are resulted from ANOVA.

[‡] Without adjustment (crude model).

[§] Additionally adjusted for other characteristics including socioeconomic status, parents' educations, family history of chronic disease, sedentary lifestyle.

Additionally adjusted for BMI in all abnormalities except for overweight and obesity.

Odds ratio (95% CIs) for cardiovascular risk factors by categories of sleep duration* ages 14–18 y: The CASPIAN-III Study

	Sleep duration (h/d)		P-value [†]
	5-8/<5	8>/<5	
Boys			
Overweight			
Model I [‡]	1.27 (0.67–2.40)	0.98 (0.53-1.83)	0.216
Model III [§]	1.51 (0.57-4.03)	1.24 (0.47–3.28)	0.554
Generalized obesity			
Model I ⁺	1.27 (0.67–2.40)	0.98 (0.53–1.83)	0.288
Model III ³	1.51 (0.57–4.03)	1.24 (0.47–3.28)	0.490
Abdominal obesity			
Model I*	1.82(0.70-4.72)	1.25 (0.49–3.20)	0.025
	2.01(0.46-8.78)	1.50(0.34-0.48)	0.512
Uigh IDI	0.42 (0.15-1.14)	0.50 (0.19-1.54)	0.855
	0.67(0.28, 1.17)	0.55 (0.22, 0.04)	0.215
Model III [§]	0.07 (0.38 - 1.17) 0.83 (0.36 - 1.89)	0.53(0.52-0.54) 0.77(0.34-1.74)	0.215
Model IV	0.03(0.50-1.03) 0.42(0.15-1.14)	0.57(0.54-1.74) 0.50(0.19-1.34)	0.676
High TC	0.12 (0.13 1.11)	0.50 (0.15 1.51)	0.070
Model I [‡]	1.60(0.47-5.45)	1 54 (0 47-5 08)	0 722
Model III [§]	2.67(0.35-20.63)	2.72(0.35-20.80)	0.546
Model IV	2.65 (0.34-20.45)	2.71 (0.35-20.78)	0.536
High TG			
Model I [‡]	0.57 (0.26-1.26)	0.47 (0.22–1.00)	0.066
Model III [§]	0.81 (0.23–2.88)	0.81 (0.23-2.85)	0.869
Model IV	0.76 (0.21-2.73)	0.76 (0.21-2.70)	0.817
Elevated FBS			
Model I [‡]	3.98 (0.94–16.87)	3.22 (0.77-13.48)	0.834
Model III [§]	2.26 (0.51-9.95)	1.57 (0.36-6.84)	0.343
Model IV	2.26 (0.51-9.93)	1.59 (0.36-6.94)	0.389
Elevated blood pressure			
Model I [‡]	0.51 (0.22–1.18)	0.47 (0.21–1.04)	0.151
Model III ⁸	0.87 (0.25-3.06)	0.77 (0.22–2.66)	0.585
Model IV	0.78 (0.22–2.77)	0.72 (0.21–2.53)	0.638
Girls			
Overweight		0.02 (0.42, 4.50)	0.501
Model I*	0.66(0.33 - 1.31)	0.83(0.43 - 1.59)	0.591
	0.63 (0.25-1.57)	0.62 (0.26-1.52)	0.515
	0.66(0.33 - 1.31)	0.83(0.43 - 1.59)	0 345
Model III [§]	0.63(0.25-1.57)	0.62(0.26-1.52)	0.943
Abdominal obesity	0.05 (0.25 1.57)	0.02 (0.20 1.32)	0.545
Model I [‡]	0.85 (0.32-2.29)	1 11 (0 43-2 86)	0.655
Model III [§]	1.37(0.30-6.16)	1.25 (0.28-5.52)	0.376
Model IV	0.78 (0.21–2.80)	1.46 (0.42–5.06)	0.119
High LDL	· · · ·	· · · ·	
Model I [‡]	0.59 (0.31-1.14)	0.76 (0.41-1.41)	0.045
Model III [§]	0.80 (0.31-2.08)	1.03 (0.40-2.63)	0.897
Model IV	0.78 (0.21-2.80)	1.46 (0.42-5.06)	0.866
High TC			
Model I [‡]	0.56 (0.15-2.07)	0.59 (0.17-2.03)	0.676
Model III [§]	0.49 (0.10-2.45)	0.54 (0.11-2.61)	0.773
Model IV	0.42 (0.08-2.13)	0.44 (0.09–2.13)	0.610
High TG			
Model I [‡]	0.76 (0.30-1.92)	0.75 (0.31–1.83)	0.673
Model III ⁸	0.47 (0.16–1.37)	0.50 (0.17–1.44)	0.544
Model IV	0.37 (0.12–1.12)	0.41 (0.14–1.23)	0.521
Elevated FBS			
	0.98 (0.44-2.22)	1.20 (0.55–2.62)	0.281
	2.81 (0.64–12.42)	3.29 (0.75–14.44)	0.144
Model IV	2.84 (0.64–12.55)	3.32 (0.76-14.56)	0.143
Elevated blood pressure			0.000
IVIODEI I*	1.14 (0.4b - 2.82)	1.08 (0.45 - 2.58)	0.932
	1.48 (U.33-0.02) 1.51 (0.22, 6.06)	1.54 (0.35-6.79)	0.670
	1.51 (0.33-0.90)	1.00 (0.37–7.51)	0.531

ANOVA, analysis of variance; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; FBS, fasting blood sugar; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglyceride

CVD abnormalities following criteria, according to Adult Treatment Panel III. Criteria modified for children and adolescents: overweight: BMI $85^{th}-95^{th}$; obesity, BMI $> 95^{th}$; low HDL: < 50 mg/dL; high to ys 15-19 y old, that cut-off was < 45 mg/dL; high LDL: >110 mg/dL; high TG: $\geq 100 \text{ mg/dL}$; high TC: > 200 mg/dL; elevated FBS > 100 mg/dL; high blood pressure: $> 95^{th}$ (adjusted by age, sex, height)

Sleep duration.

P-value are resulted from regression.

[‡] Without adjustment (crude model).

[§] Additionally adjusted for other characteristics including socioeconomic status, parents' educations, family history of chronic disease, sedentary lifestyle.

Additionally adjusted for BMI in all abnormalities except for overweight and obesity.

Additionally, dysregulation of the autonomic nervous system may play a role in the association between sleep deprivation and obesity, which is mediated by elevation of hypothalamicpituitary-adrenal (HPA) axis activity and activated systemic inflammatory processes [35]. Short sleep duration usually is related to less physical activity and more stress, which can increase the catecholamine-induced lipolysis, TC, and LDL levels [32]. Observed association between sleep restriction and higher LDL-C levels among girls may be related to sex discrepancy in factors associated with the risk factors for high cholesterol [32].

Our study has some limitations and notable strengths. To our knowledge, it is the first study conducted to evaluate the association of sleep duration and CVD risk factors in Iran. The strengths of our study include a large, nationally representative sample size and consideration of the role of potential confounders in the data analysis. Moreover, our study participants included both girls and boys who were analyzed separately. There were several limitations in this study. First, the cross-sectional nature of the study, which limited us from getting information on the causal relationship of sleep duration and CVD risk factors. Second, sleep duration was self-reported by participants, which may include misclassification. However, studies have reported a good correlation between self-reported sleep duration and quantitative sleep assessment with actigraphy. Third, we measured only the quantity of sleep but not the quality such as the presence or absence of sleep apnea, which is associated with increased risk for CVDs. It is possible that despite adequate sleep duration, poor quality of sleep is associated with detrimental effects on obesity and other CVD risk factors. Our findings may propose new attitudes into the relationship between lifestyle and health. The promotion of lifestyle modification in early life to get enough sleep and to avoid habitual sleep restriction can help improve present and future health status.

Conclusion

Our observation showed that short sleep duration was independently associated with high LDL-C among children and adolescents. Moreover, a positive association was found between sleep duration and mean TC among boys ages 10 to 14 y. More prospective studies with the purpose of assessing long-term exposure (e.g., repeated actigraphy) and better control for confounding variables such as sleep disturbance are required. If our findings are supported by future prospective studies, avoiding unsuitable sleep duration can be considered a primary preventive program against development of chronic diseases, notably CVDs in adulthood.

References

- Rafraf M, Gargari B. Prevalence of prehypertension and hypertension among adolescent high school girls in Tabriz, Iran. Food Nutr Bull 2010;31:461–5.
- [2] Hamidi A, Fakhrzadeh H. Obesity and associated cardiovascular risk factors in Iranian children: a cross-sectional study. Pediatr Int 2006;48:566–71.
- [3] Harriss LR, English DR. Dietary pattern and cardiovascular mortality in the Melbourne collaborative cohort study. Am | Clin Nutr 2007;86:221–9.
- [4] Manios Y, Dimitriou M. Cardiovascular disease risk factors among children of different socioeconomic status in Istanbul, Turkey: directions for public health and nutrition policy. Lipids Health Dis 2004;3:11.
- [5] Buxton O, Marcelli E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in United States. SocSci Meds 2010;71:1027–36.
- [6] Amagai Y, Ishikawa S. Sleep duration and incidence of cardiovascular events in a Japanese population: the jichi medical school cohort study. J Epidemiol 2010;20:106–10.

- [7] Leproult R, Cauter EV. Role of sleep and sleep loss in hormonal release and metabolism. Endocr Dev 2010;17:11–21.
- [8] Ayatollahi SMT. Prevalence of obesity among schoolchildren in Iran. Natl Prev Obes 2007;8:289–91.
- [9] Kong A, Wing YK. Association of sleep duration with obesity and lipid profile in children and adolescents. Sleep Med 2011;12:659–65.
- [10] Carcia E, Faubel R. Sleep duration, general and abdominal obesity, and weight change among the older adult population of Spain. Am J Clin Nutr 2008;87:310–6.
- [11] Falaschetti E, Hingorani AD. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. Eur Heart J 2010;31:3063–72.
- [12] Sung V, Beebe DW. Does sleep duration predict metabolic risk in obese adolescents attending tertiary services? a cross-sectional study. Sleep 2011;34:891–8.
- [13] Guo X, Zheng L. Association between sleep duration and hypertension among Chinese children and adolescents. Clin Cardiol 2011;34:774–81.
- [14] Flint J, Kothare SV, Zihlif M, Suarez E, Adams R, Legido A, et al. Association between inadequate sleep and insulin resistance in obese children.[see comment]. J Pediatr 2007;150:364–9.
- [15] Verhulst SL, Schrauwen N, Haentjens D, Rooman RP, Van Gaal L, De Backer WA, et al. Sleep duration and metabolic dysregulation in overweight children and adolescents. Arch Dis Child 2008;93:89–90.
- [16] Kelishadi R, Heshmat R, Motlagh ME, Majdzadeh R, Keramatian K, Qorbani M, et al. Methodology and early findings of the Third Survey of CASPIAN Study: A national school-based surveillance of students' high risk behaviors. Int J Prev Med 2012;3:394–401.
- [17] Kelishadi R, Ardalan G, Gheiratmand R, Gouya MM, Razaghi EM, Delavari A, et al, CASPIAN Study Group. Association of physical activity and dietary behaviours in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bull World Health Organ 2007;85:19–26.
- [18] Kuczmarski RJ, Ogden CL, Grummer-Strawn LM. CDC growth charts: United States. Adv Data 2000;314:1–27.
- [19] Lipid Research Clinics Population Studies Data Book. NIH Publication No. 80-1527. The Prevalence Study, vol. 1. Washington, DC: National Institutes of Health; 1980.
- [20] Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3.
- [21] National High Blood Pressure Education Program. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 1996;98: 649–58.
- [22] Jarrin DC, McGrath JJ, Drake CL. Beyond sleep duration: distinct sleep dimensions are associated with obesity in children and adolescents. Int J Obes (Lond). 2013;37:552–8.
- [23] Hasler G, Buysse DJ, Klaghofer R, Gamma A, Ajdacic V, Eich D, et al. The association between short sleep duration and obesity in young adults: a 13-year prospectivestudy. Sleep 2004;27:661–6.
- [24] Chaput JP, Brunet M, Tremblay A. Relationship between short sleeping hours and childhood overweight/obesity: results from the 'Quebec en Forme' project. Int J Obes 2006;30:1080–5.
- [25] Gupta NK, Mueller WH, Chan W, Meininger JC. Is obesity associated with poor sleep quality in adolescents? Am J Hum Biol 2002;14:762–8.
- [26] Sekine M, Yamagami T, Hamanishi S, Handa K, Saito T, Nanri S, et al. Parental obesity, lifestyle factors and obesity in preschool children: results of the Toyama birth cohort study. J Epidemiol 2002;12:33–9.
- [27] Knutson KL. Sex differences in the association between sleep and body mass index in adolescents. J Pediatr 2005;147:830–4.
- [28] Williams CJ, Patel SR. Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. Diabetes Care 2007;30:1233–40.
- [29] Stranges SP, Cappuccio F. Cross-sectional versus prospective associations of sleep duration with changes in relative weight and body fat distribution: the Whitehall II Study. Am J Epidemiol 2008;167:321–9.
- [30] Knutson KL. Sleep duration and cardiometabolic risk: a review of the epidemiologic evidence. Best Pract Res Clin Endocrinol Metab 2010;24: 731–43.
- [31] Haghighatdoost F, Karimi G, Esmaillzadeh A, Azadbakht L. Sleep deprivation is associated with lower diet quality indices and higher rate of general and central obesity among young female students in Iran. Nutrition 2012;28:1146–50.
- [32] Gangwisch JE, Malaspina D. Short sleep duration as a risk factor for hypercholesterolemia: analyses of the national longitudinal study of adolescent health. Sleep 2010;33:956–61.
- [33] Gangwisch JE, Malaspina D, Babiss LA, Opler MG, Posner K, Shen S, et al. Short sleep duration as a risk factor for hypercholesterolemia: analyses of the national longitudinal study of adolescent health. Sleep 2010;33: 956–61.
- [34] Cauter VE, Knutson KL. Sleep and the epidemic of obesity in children and adults. Eur J Endocrinol 2008;159:S59–66.

- [35] Itani O, Kaneita Y. Association of onset of obesity with sleep duration and shift work amongJapanese adults. Sleep Med 2011;12:341–5.
- [36] Nagai M, Hoshide S. Sleep duration as a risk factor for cardiovascular disease- a review of the recent literature. Curr Cardiol Rev 2010;6:54–61.[37] Javaheri S, Isser SA. Association of short and long sleep durations with
- insulin sensitivity in adolescents. J Pediatr 2011;158:617–23.
- [38] Gangwisch EJ, Heymsfield BS. Short sleep duration as a risk factor for hypertension analyses of the first National Health and Nutrition Examination Survey. Hypertension 2006;47:833–9.
- [39] Liu R, Zee CP. Short sleep duration is associated with insulin resistance independent of adiposity in Chinese adult twins. Sleep Med 2011;12: 914–9.